Home » Stocks » ARDS

Aridis Pharmaceuticals Inc. (ARDS)

Stock Price: $6.89 USD -0.12 (-1.71%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 69.35M
Revenue (ttm) 1,000,000
Net Income (ttm) -22.16M
Shares Out 8.92M
EPS (ttm) -2.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $6.89
Previous Close $7.01
Change ($) -0.12
Change (%) -1.71%
Day's Open 7.25
Day's Range 6.89 - 7.29
Day's Volume 18,112
52-Week Range 4.34 - 8.97

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 month ago

SAN JOSE, Calif., Nov. 24, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therap...

PRNewsWire - 2 months ago

SAN JOSE, Calif., Nov. 20, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therap...

PRNewsWire - 2 months ago

SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therap...

PRNewsWire - 3 months ago

SAN JOSE, Calif., Oct. 19, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therap...

PRNewsWire - 3 months ago

SAN JOSE, Calif., Oct. 14, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (the "Company"), a biopharmaceutical company focused on the discovery and development of novel anti-...

PRNewsWire - 4 months ago

SAN JOSE, Calif., Sept. 8, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc.

PRNewsWire - 4 months ago

SAN JOSE, Calif., Sept. 4, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc.

PRNewsWire - 5 months ago

SAN JOSE, Calif., Aug. 11, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc.

PRNewsWire - 6 months ago

SAN JOSE, Calif., June 26, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therap...

Benzinga - 7 months ago

The SPDR S&P 500 (NYSE: SPY) started off the week on a high note on Monday morning after a turbulent week of trading last week.

Other stocks mentioned: CGC, DB, DRI, HSBC, KPTI, NKE, UBS, ZGNX
PRNewsWire - 7 months ago

SAN JOSE, Calif., June 22, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therap...

PRNewsWire - 7 months ago

SAN JOSE, Calif., June 15, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therap...

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor Aridis Pharmaceuticals

Benzinga - 1 year ago

Shares of the thinly traded, micro-cap biotech Aridis Pharmaceuticals Inc (NASDAQ: ARDS) were retreating to a one-week low Tuesday morning.

Market Watch - 1 year ago

Shares of Aridis Pharmaceuticals Inc. plunged 27% to pace all premarket decliners Tuesday, after the biopharmaceutical company said a phase 2 trial of its treatment of ventilator-associated pn...

Zacks Investment Research - 1 year ago

Aridis Pharmaceuticals has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

About ARDS

Aridis Pharmaceuticals, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-... [Read more...]

Industry
Biotechnology
IPO Date
Aug 10, 2018
Stock Exchange
NASDAQ
Ticker Symbol
ARDS
Full Company Profile

Financial Performance

In 2019, ARDS's revenue was $1.02 million, a decrease of -62.93% compared to the previous year's $2.76 million. Losses were -$29.68 million, 34.3% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for ARDS stock is "Buy." The 12-month stock price forecast is 17.20, which is an increase of 149.64% from the latest price.

Price Target
$17.20
(149.64% upside)
Analyst Consensus: Buy